Premium
Cutaneous Toxicities From Transplantation‐Related Medications
Author(s) -
Ilyas M.,
Colegio O. R.,
Kaplan B.,
Sharma A.
Publication year - 2017
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.14337
Subject(s) - medicine , basiliximab , daclizumab , sirolimus , azathioprine , tacrolimus , transplantation , everolimus , organ transplantation , toxic epidermal necrolysis , belatacept , immunosuppression , intensive care medicine , dermatology , kidney transplantation , disease , kidney transplant
Despite the abundance of information on cutaneous malignancies associated with solid organ transplantation in the transplant literature, there is limited information regarding nonmalignant skin changes after transplantation. There are numerous skin toxicities secondary to immunosuppressive and other transplant‐related medications that can vary in presentation, severity, and prognosis. To limit associated morbidity and mortality, solid organ transplant recipient care providers should effectively identify and manage cutaneous manifestations secondary to drug toxicity. Toxicities from the following transplant‐related medications will be discussed: antithymocyte globulins, systemic steroids, cyclosporine, tacrolimus, azathioprine, mycophenolate mofetil, mammalian target of rapamycin inhibitors sirolimus and everolimus, basiliximab and daclizumab, belatacept, and voriconazole.